A six-year study on implantable cardioverter defibrillators (ICDs) and their impact on the health outcomes of heart failure patients has been awarded $27 million in research funding by the University of Rochester Medical Center. This grant is considered one of the largest awards received by URMC in the last decade.
The aim of this study is to determine if advancements in medical therapy could potentially reduce the need for ICDs in many individuals living with heart failure. Dr. Ilan Goldenberg, the director of the Clinical Cardiovascular Research Center and lead investigator of the study, believes that current analysis suggests that a significant portion of patients who receive ICDs may not actually benefit from them in terms of survival.
If the study’s findings support Dr. Goldenberg’s hypothesis, it could lead to changes in practice guidelines for managing heart failure. Over 3,000 patients will be enrolled in this study, which will take place at 115 sites across the United States and Canada. The impact of this research could be groundbreaking in terms of improving care and outcomes for patients with heart failure.
URMC considers this grant one of its largest awards received in recent years, reflecting its commitment to advancing medical research and improving patient care on a global scale.
